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Abstract
Over 5,000 participants attended the 10th International Conference on Alzheimer's Disease
(ICAD) and Related Disorders in Madrid, Spain from July 15–20, 2006. Highlights of the conference
included reports on brain imaging, the discovery of mutations in the progranulin gene that cause
frontotemporal dementia, the finding that neuregulin-1 is a substrate for BACE1 and new interest
in the connection between Alzheimer's disease and metabolic syndromes.
The 10th International Conference on Alzheimer's Disease
(ICAD) and Related Disorders was held in the Spanish
capitol of Madrid from July 15–20, 2006. More than
5,000 researchers, students and clinicians came to Madrid
to present their research and learn about the findings of
others. The welcome reception at Palacio Negralejo, a
sprawling estate on the outskirts of Madrid, allowed
attendees to meet collaborators and friends and sample
some typical Spanish food: Iberic ham, seafood paella,
grilled veal and various tapas. Flamenco dancers, banjo
players, and plenty of sangria created a festive beginning
for the conference.
The main conference was preceded by an imaging consor-
tium on Alzheimer's disease (AD). Using a wide variety of
methods, investigators showed correlations between AD
or aging and different imaging measures. There was partic-
ular interest in white matter lesions, which several scien-
tists noted were closely correlated with AD. Frank-Erik De
Leeuw from UMC-Stradboud in the Netherlands reported
that the extent of white matter lesions correlates with
medial temporal atrophy in late-onset but not early-onset
AD, suggesting that late-onset and early-onset AD may
have some different pathological pathways [1]. There
were also several reports on brain PET imaging using the
Pittsburgh compound B (PiB). William Klunk from the
University of Pittsburgh estimated that over 500 patients
at 12 institutions have undergone PET scans using PiB,
which appears to be a reliable marker of amyloid deposi-
tion [2]. It is hoped that imaging will identify patients at
risk for AD and differentiate patients with amyloid-β dep-
osition from patients with other types of pathology.
Although there were hundreds of presentations at ICAD, a
few stood out because of their importance and novelty.
Perhaps the biggest news came from two independent
groups of researchers at the Mayo Clinic and the Univer-
sity of Antwerp in Belgium. Both groups found mutations
in the gene encoding progranulin that cause a form of
frontotemporal dementia (FTD), the second most com-
mon form of dementia in individuals younger than 65
years old [3,4]. Since 1998, when mutations in the micro-
tubule-associated protein tau (MAPT) gene on chromo-
some 17 were found to cause FTD with parkinsonism,
geneticists have been stymied by families with FTD linked
to the same region on chromosome 17 but having no
MAPT mutations. It seemed likely that difficult-to-find
mutations in MAPT accounted for these FTD cases, but the
mutations could not be found despite heroic efforts.
Geneticists then sequenced genes near MAPT and were
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(PGRN), which is located a mere 1.7 Mb away from
MAPT. In one patient series, PGRN mutations accounted
for at least 11% of all FTD cases and 26% of familial FTD
cases. Interestingly, all the PRGN mutations that were
reported are dominant and effectively create null alleles,
meaning that the FTD phenotype results from decreased
levels of progranulin in affected individuals. Additionally,
the ubiquitin-positive inclusions in the brains of affected
individuals do not stain with anti-progranulin antibodies,
leaving the identity of the ubiquitinated protein an
intriguing mystery. The discovery of PGRN mutations is a
major advance in our understanding of FTD and will
undoubtedly inspire intense research to discover the
mechanism by which progranulin deficiency leads to FTD.
Another interesting story from the conference involved
BACE1, the major β-secretase in the brain. Sequential
cleavage of amyloid precursor protein by β-secretase and
then γ-secretase produces the amyloid β-peptide (Aβ).
Since inhibition of β-secretase should decrease Aβ levels
in the brain, it is an attractive therapeutic target. In fact,
Martin Citron from Amgen reported that over 100 patents
have been filed for BACE1 inhibitors [5]. However, inhi-
bition of BACE1 could have negative consequences if
other molecules that are physiologically important
require cleavage by BACE1. Christian Haass and his col-
leagues in Germany were attempting to find normal sub-
strates for BACE1 and began with two key observations: 1.
BACE1 expression is high post-natally but low in adults
and 2. BACE1 is not expressed by invertebrates. From
these clues, Haass and his colleagues thought that BACE1
may be involved in myelination, which is prominent in
the post-natal time interval and is not present in inverte-
brates. Their hypothesis was correct: electron microscopic
examination of the peripheral nerves from BACE1 defi-
cient mice showed pronounced hypomyelination [6].
Interestingly, this hypomyelination phenotype was simi-
lar to that of neuregulin-1 haploinsufficient mice, which
led Haass and his colleagues to hypothesize that neuregu-
lin-1 was a substrate for BACE1. Next they found that neu-
regulin-1 levels are elevated in the brains of Bace1-/- mice,
most likely because BACE1 is the major enzyme that
cleaves neuregulin-1. Finally, they demonstrated that neu-
regulin-1 is cleaved by BACE1 in vitro [7]. It is unknown
whether inhibition of neuregulin-1 cleavage in adults, as
could occur with the therapeutic usage of BACE1 inhibi-
tors, would create adverse effects. Since myelination pri-
marily occurs in childhood, decreased neuregulin-1
cleavage in older adults may not be an issue, but this
remains to be proven. Overall, this was a remarkable story
because the investigators deduced such a large amount of
information from two seemingly small observations.
An area that has not been previously emphasized, the
interaction between AD and metabolic syndromes such as
obesity and diabetes, was discussed in multiple sessions.
Miia Kivipelto from the Stockholm Gerontology Research
Center presented epidemiological data showing that obes-
ity, hypercholesterolemia and hypertension were all risk
factors for AD and that when all three factors were present
in the same individual the risk of AD increased 6-fold [8].
Other investigators found links between diabetes, periph-
eral insulin resistance, cerebral glucose metabolism and
cognitive dysfunction, but the mechanisms involved were
not clear. However, a possible connection between AD
and metabolic syndromes has important therapeutic
implications. Previous studies have shown that intrave-
nous (IV) insulin administration improves cognition in
AD patients, but IV insulin is not a viable therapeutic
option due to the risk of hypoglycemia. To circumvent the
risk of hypoglycemia and deliver insulin to the brain,
Suzanne Craft from the University of Washington treated
subjects with either early AD or mild cognitive impair-
ment with daily intranasal insulin or placebo. After 21
days, the patients treated with intranasal insulin had bet-
ter memory-related scores [9]. Another group, from Glax-
oSmithKline, also performed a clinical trial of a diabetes-
related drug. They treated 511 AD subjects with the type-
2 diabetes drug rosiglitazone or placebo for 24 weeks, but
found no clinical improvement on several different tests
[10]. Clearly, further studies are required to determine
how AD is connected to metabolic disorders and whether
drugs that are commonly used to treat metabolic diseases
are beneficial to AD patients.
Finally, one other notable change in this conference was
the plethora of drug company representatives marketing
their formulations of acetylcholinesterase inhibitors and
memantine. While scientists rarely get excited about
increasing numbers of drug salespeople, their presence
was evidence that therapeutics the Alzheimer's research
and pharmaceutical community has been developing for
years are finally coming to the market. Hopefully the ther-
apeutics being marketed at the 2008 ICAD conference in
Chicago will be more numerous and effective.
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